» Articles » PMID: 35682804

Transcriptional Basis of Psoriasis from Large Scale Gene Expression Studies: The Importance of Moving Towards a Precision Medicine Approach

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Jun 10
PMID 35682804
Authors
Affiliations
Soon will be listed here.
Abstract

Transcriptome profiling techniques, such as microarrays and RNA sequencing (RNA-seq), are valuable tools for deciphering the regulatory network underlying psoriasis and have revealed large number of differentially expressed genes in lesional and non-lesional skin. Such approaches provide a more precise measurement of transcript levels and their isoforms than any other methods. Large cohort transcriptomic analyses have greatly improved our understanding of the physiological and molecular mechanisms underlying disease pathogenesis and progression. Here, we mostly review the findings of some important large scale psoriatic transcriptomic studies, and the benefits of such studies in elucidating potential therapeutic targets and biomarkers for psoriasis treatment. We also emphasised the importance of looking into the alternatively spliced RNA isoforms/transcripts in psoriasis, rather than focussing only on the gene-level annotation. The neutrophil and blood transcriptome signature in psoriasis is also briefly reviewed, as it provides the immune status information of patients and is a less invasive platform. The application of precision medicine in current management of psoriasis, by combining transcriptomic data, improves the clinical response outcome in individual patients. Drugs tailored to individual patient's genetic profile will greatly improve patient outcome and cost savings for the healthcare system.

Citing Articles

Factors Affecting Treatment Persistence in Japanese Patients with Psoriasis Prescribed Biologics: A Real-World Study Using an Insurance Claim Database.

Miyazaki C, Masuda J, Tsai P, Saeki H Dermatol Ther (Heidelb). 2024; 14(11):2999-3015.

PMID: 39407051 PMC: 11557743. DOI: 10.1007/s13555-024-01274-1.


Integrative analysis of gene and microRNA expression profiles reveals candidate biomarkers and regulatory networks in psoriasis.

Chen L, Wang X, Liu C, Chen X, Li P, Qiu W Medicine (Baltimore). 2024; 103(29):e39002.

PMID: 39028999 PMC: 11398825. DOI: 10.1097/MD.0000000000039002.


Improvement effects of a novel Chinese herbal formula in imiquimod and IL-23-stimulated mouse models of psoriasis.

Wang L, Dou Y, Yu Q, Hu Z, Ip S, Xian Y Chin Med. 2024; 19(1):81.

PMID: 38858762 PMC: 11165727. DOI: 10.1186/s13020-024-00951-9.


Psoriasis and Psoriatic Arthritis-Associated Genes, Cytokines, and Human Leukocyte Antigens.

Zalesak M, Danisovic L, Harsanyi S Medicina (Kaunas). 2024; 60(5).

PMID: 38792999 PMC: 11123327. DOI: 10.3390/medicina60050815.


Transcriptional Landscape of Repetitive Elements in Psoriatic Skin from Large Cohort Studies: Relevance to Psoriasis Pathophysiology.

Krishnan V, Koks S Int J Mol Sci. 2023; 24(23).

PMID: 38069048 PMC: 10706217. DOI: 10.3390/ijms242316725.


References
1.
Bando M, Hiroshima Y, Kataoka M, Shinohara Y, Herzberg M, Ross K . Interleukin-1alpha regulates antimicrobial peptide expression in human keratinocytes. Immunol Cell Biol. 2007; 85(7):532-7. DOI: 10.1038/sj.icb.7100078. View

2.
Koks S, Keermann M, Reimann E, Prans E, Abram K, Silm H . Psoriasis-Specific RNA Isoforms Identified by RNA-Seq Analysis of 173,446 Transcripts. Front Med (Lausanne). 2016; 3:46. PMC: 5053979. DOI: 10.3389/fmed.2016.00046. View

3.
Chang H, Yan D, Singh R, Bui A, Lee K, Truong A . Multiomic Analysis of the Gut Microbiome in Psoriasis Reveals Distinct Host‒Microbe Associations. JID Innov. 2022; 2(3):100115. PMC: 9214347. DOI: 10.1016/j.xjidi.2022.100115. View

4.
Sun L, Cheng H, Wang Z, Zhang A, Wang P, Xu J . Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet. 2010; 42(11):1005-9. PMC: 3140436. DOI: 10.1038/ng.690. View

5.
Mehrmal S, Uppal P, Nedley N, Giesey R, Delost G . The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: A systematic analysis from the Global Burden of Disease Study 2017. J Am Acad Dermatol. 2020; 84(1):46-52. DOI: 10.1016/j.jaad.2020.04.139. View